CSTL insider trading
HealthcareCASTLE BIOSCIENCES INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About CASTLE BIOSCIENCES INC
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Company website: castlebiosciences.com
CSTL insider activity at a glance
FilingIQ has scored 2,521 insider transactions for CSTL since Jul 29, 2019. The most recent filing in our index is dated May 7, 2026.
Across the full history, 13 open-market purchases
and 2,228 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CSTL insider trades is 57.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CSTL Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CSTL?
- FilingIQ tracks 2,521 Form 4 insider transactions for CSTL (CASTLE BIOSCIENCES INC), covering filings from Jul 29, 2019 onwards. 94 of those were filed in the last 90 days.
- Are CSTL insiders net buyers or net sellers?
- Across the full Form 4 history for CSTL, 13 transactions (1%) were open-market purchases and 2,228 (88%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CSTL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CSTL in?
- CASTLE BIOSCIENCES INC (CSTL) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $968.48M.
Methodology & sources
Every CSTL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.